FRLN News and Press, Freeline Therapeutics Holdings plc From 11/21/23

Freightos Limited (CRGO) is expected to report $-0.14 for Q3 2023 Magyar Telekom Telecommunications ADR (MYTAY) is expected to report for Q3 2023 IMAC Holdings Inc. (BACK) is expected to report for Q1 2024 NewJersey Resources Corporation (NJR) is expected to report $0.3 for Q4 2023 ...

Freeline Therapeutics Holdings plc (FRLN) is expected to report $-0.2 for Q3 2023

Frontline plc (the “Company”) announces that its 2023 Annual General Meeting will be held on December 12, 2023. A copy of the Notice of Annual General Meeting and associated information including the Company’s Annual Report on Form 20-F for 2022 can be found on our website at...

Frontline plc (the “Company”) advises that the 2023 Annual General Meeting of the Company will be held on December 12, 2023. The record date for voting at the Annual General Meeting is set to November 20, 2023. The notice, agenda and associated material will be distributed prior to ...

Substantial reduction in lyso-Gb1 substrate levels, an established biomarker of clinical response, observed in first patient treated with FLT201 Increases of several hundredfold over baseline in plasma GCase activity and normalization of cellular GCase levels continue to be observed in fi...

2023-10-18 12:10:20 ET More on Freeline Therapeutics Freeline Therapeutics Holdings plc (FRLN) Q2 2023 Earnings Call Transcript Freeline posts early data for gene therapy in Gaucher disease Freeline Therapeutics GAAP EPS of -$0.23 beats by $3.28, revenue of $0.62M ...

2023-10-18 10:00:01 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further...

2023-10-18 08:21:09 ET Ardelyx  ( ARDX ) +18% granted FDA nod for kidney disease therapy. Connexa Sports Technologies ( CNXA ) +14% . Spirit Aerosystems  ( SPR ) +10% Boeing Reach Agreement to Support Production Stability. Freeline Therapeutic...

LONDON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will present new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate, in patients with Gaucher disease Ty...

Please find enclosed the presentation in relation to Frontline plc´s investor call to be held on the webcast / conference call October 9, 2023 at 15:00 CET. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. ...